ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone914-207-2300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees23
OptionableNot Optionable
ContraFect (NASDAQ:CFRX) Frequently Asked Questions
What is ContraFect's stock symbol?
ContraFect trades on the NASDAQ under the ticker symbol "CFRX."
How were ContraFect's earnings last quarter?
ContraFect Corp (NASDAQ:CFRX) announced its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04. View ContraFect's Earnings History.
When is ContraFect's next earnings date?
What price target have analysts set for CFRX?
3 analysts have issued 1 year price targets for ContraFect's stock. Their forecasts range from $2.80 to $2.80. On average, they expect ContraFect's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 409.1% from the stock's current price. View Analyst Price Targets for ContraFect.
What is the consensus analysts' recommendation for ContraFect?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.
Has ContraFect been receiving favorable news coverage?
Media coverage about CFRX stock has trended very positive on Tuesday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ContraFect earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Are investors shorting ContraFect?
ContraFect saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 958,556 shares, an increase of 68.5% from the December 14th total of 568,940 shares. Based on an average daily volume of 262,292 shares, the days-to-cover ratio is currently 3.7 days. Currently, 1.7% of the company's stock are short sold. View ContraFect's Current Options Chain.
Who are some of ContraFect's key competitors?
Some companies that are related to ContraFect include Aquestive Therapeutics (AQST), VBI Vaccines (VBIV), ProMetic Life Sciences (PFSCF), Recro Pharma (REPH), Calithera Biosciences (CALA), Constellation Pharmaceuticals (CNST), Ocular Therapeutix (OCUL), AcelRx Pharmaceuticals (ACRX), Molecular Templates (MTEM), Nature's Sunshine Products (NATR), CytoDyn (CYDY), MOTIF BIO PLC/S (MTFB), Emisphere Technologies (EMIS), Poxel (PXXLF) and REDHILL BIOPHAR/S (RDHL).
Who are ContraFect's key executives?
ContraFect's management team includes the folowing people:
- Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 65)
- Mr. Michael Messinger, CFO & Chief Accounting Officer (Age 43)
- Ms. Nancy Dong, VP of Fin. & Admin. (Age 53)
- Ms. Natalie Bogdanos J.D., Gen. Counsel & Corp. Sec. (Age 49)
- Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 56)
How do I buy shares of ContraFect?
Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ContraFect's stock price today?
One share of CFRX stock can currently be purchased for approximately $0.55.
How big of a company is ContraFect?
ContraFect has a market capitalization of $43.68 million. The biotechnology company earns $-15,510,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 23 workers across the globe.
What is ContraFect's official website?
How can I contact ContraFect?
ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]
MarketBeat Community Rating for ContraFect (NASDAQ CFRX)
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
